WilmerHale Advises PyrAmes in Series B Financing

WilmerHale Advises PyrAmes in Series B Financing

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale advised PyrAmes in the initial close of its Series B financing round, led by a strategic investor.

PyrAmes is a digital health company focused on continuous blood pressure monitoring. The financing will support expanded commercial sales of Boppli®, the company’s FDA cleared continuous and noninvasive blood pressure monitoring solution for critically ill infants, as well as the commercial launch of its monitoring product for adults.

The WilmerHale team was led by Daniel Zimmerman and included Gabriella Stearns, Matteo de Suduiraut, Ciara Baker, Jason Chipman and Amanda Rossetta.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel